Suzanne Roghieh Saffie-Siebert

SiSaf Ltd. engages in the design and formulation of drugs for topical delivery systems. Its proprietary technology represents a highly effective, non-irritant carrier for cosmetic and medical products, where improved skin penetration, targeting, and controlled release are required. The firm uses nanosilicon as a carrier for active compounds allowing them to penetrate deep beneath the skin's epidermal barrier for controlled release. It operates through its offices located in Belfast and San Jose. The company was founded by Suzanne Roghieh Saffie-Siebert and Timothy John Brundle in 2006 and is headquartered in Belfast, the United Kingdom.

Dompé SpA provides services of updating and scientific assistance to doctors. It offers information on therapeutic areas including physiatrics, cystic fibrosis, geriatrics, infectious diseases, internal, sleep and sports medicine, odontology, orthopedics and traumatology, otorhinolaryngology, pediatrics, pneumology, and emergency and drugs. The company was founded by Sergio Dompé in 1993 and is headquartered in L'Aquila, Italy.

Autism Biotech Ltd. researches and develops biotechnology. The company was founded by Suzanne Roghieh Saffie-Siebert in 2012 and is headquartered in Queens Island, the United Kingdom.

Part of EyePoint Pharmaceuticals, Inc., pSiMedica Ltd. is a British company that researches and develops nanostructured porous silicon. The company is based in Malvern, UK. The company was founded by Sam di Giacomo. The CEO is Roger Aston. pSiMedica was acquired by EyePoint Pharmaceuticals, Inc. on August 05, 2004 for $40.97 million.